EU revises GMP guide on products derived from human blood, plasma
This article was originally published in SRA
The European Commission has substantially revised its guidance on good manufacturing practice requirements for drugs derived from human blood or plasma that is fractionated in, or imported into, the EU/European Economic Area1,2. The updated guidance also applies to stable derivatives of human blood or human plasma (eg albumin) incorporated into medical devices.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.